loading page

Camelina oil in the context of a weight loss programs improves glucose homeostasis, inflammation and oxidative stress in NAFLD patients: A randomized, triple -blind, placebo-controlled clinical trial
  • +1
  • vali musazadeh,
  • parvin dehghan,
  • sevda salehghadimi,
  • Mahdieh Abbasalizad-Farhangi
vali musazadeh
Tabriz University of Medical Sciences
Author Profile
parvin dehghan
Tabriz University of Medical Sciences
Author Profile
sevda salehghadimi
Arak University of Medical Sciences
Author Profile
Mahdieh Abbasalizad-Farhangi
Tabriz University of Medical Sciences
Author Profile

Abstract

Background: Over the past few years, the benefits of co-administration of omega-3 and antioxidants have been reported in the management of non-alcoholic fatty liver disease (NAFLD) complications.This study evaluated the effects of Camelina sativa oil (CSO) supplementation as one of the richest dietary sources of omega-3 fatty acids on glucose homeostasis,inflammation, metabolic endotoxemia, and oxidative stress in NAFLD patients. Methods: In all, 43 subjects with NAFLD were allocated to either an intervention (20g/d CSO) or placebo (20g/d sunflower oil) group receiving a calorie-restricted diet for 12 weeks. Fasting serum levels of glycemic indices, hs-CRP, endotoxin, antioxidant enzymes activity, total antioxidant capacity (TAC), malondialdehyde (MDA), 8-iso-prostaglandin F2α (8-iso-PGF2α), and uric acid were measured at baseline and post-intervention. Results: CSO intake led to a significant decrease in insulin concentration (-17.49%), homeostasis model assessment of insulin resistance (HOMA-IR) (-20%), high-sensitive C-reactive protein (hs-CRP), (-12.94%), lipopolysaccharide endotoxin (-32.55%), malondialdehyde (MDA) (-18.75%), 8-iso-prostaglandin F2α (8-iso-PGF2α) (-19.55%) and a significant increase in the levels of total antioxidant capacity (TAC) (31.82%) and superoxide dismutase activity (10.22%) in the CSO group compared with the placebo group. Also, there was no significant difference between the two groups in fasting plasma glucose, quantitative insulin sensitivity check index (QUICKI), catalase, glutathione peroxidase activity, and uric acid level. In addition, within-group analyses showed a significant reduction of insulin, QUICKI, hs-CRP, and endotoxin levels in the intervention group. Conclusion: These findings indicate that CSO may improve glycemic, inflammation, metabolic endotoxima, oxidative stress status, and mental health in patients with NAFLD.

Peer review status:ACCEPTED

29 May 2021Submitted to International Journal of Clinical Practice
02 Jun 2021Submission Checks Completed
02 Jun 2021Assigned to Editor
23 Jun 2021Reviewer(s) Assigned
19 Jul 2021Review(s) Completed, Editorial Evaluation Pending
20 Jul 2021Editorial Decision: Revise Major
17 Aug 20211st Revision Received
18 Aug 2021Review(s) Completed, Editorial Evaluation Pending
18 Aug 2021Submission Checks Completed
18 Aug 2021Assigned to Editor
20 Aug 2021Editorial Decision: Accept